MoonLake Immunotherapeutics (MLTX) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

MoonLake Immunotherapeutics

MLTX

NASDAQ

Unprofitable

Unprofitable

3B

Biotechnology

Next Earning date - 12 Nov 2024

3B

Biotechnology

Next Earning date - 12 Nov 2024

48.94USD

1.94 ( 4.13%)

Relative Strenght

66

Volume Buzz

-28%

Earning Acce

No

Dist 52w H.

25%

Quote Panel

Updated October 12, 2024

1W -5.41 % 1M -4.30 % 3M 0.08 % 1Y -10.48 %

Key Metrics

Market Cap
3.08B
Shares Outstanding
62.89M
Share in Float
52.49M
Dividende
0

Earning Date
12 Nov 2024
Price Target
48.94
Average Volume
357856
Beta
1.256

Range
35.11-64.98
Industry
Biotechnology
Website
https://www.moonlaketx.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

155931.10x

P/S Ratio

5.91x

P/B Ratio

0.0

Debt/Equity

-277656.3%

Net Margin

$-0.9

EPS

How MLTX compares to sector?

P/E Ratio

Relative Strength

MLTX

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

0

$2.27

-482%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Wolfe Research

downgrade

Previous: Not converted

2024-08-26

Now: Peer Perform

Oppenheimer

initialise

Previous: Not converted

2024-06-24

Now: Outperform

Goldman Sachs

initialise

Previous: Not converted

2024-04-02

Now: Neutral

Needham

initialise

Previous: Not converted

2023-08-31

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.27
vs -0.17

Q4.22

N/A

-0.31
vs NA

Q1.23

N/A

-0.23
vs -0.43

Q2.23

N/A

-0.23
vs -0.34

Q3.23

N/A

-0.18
vs -0.27

Q4.23

N/A

-0.12
vs -0.31

Q1.24

N/A

-0.22
vs -0.23

Q2.24

N/A

-0.39
vs -0.23

Q3.24

N/A

-0.44
vs -0.18

Q4.24

N/A

-0.50
vs -0.12

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

19.7K vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

-27%

-0.27
vs -0.27

Q4.22

-34%

-0.34
vs -0.27

Q1.23

-29%

-0.29
vs -0.34

Q2.23

-2%

-0.02
vs -0.29

Q3.23

-2%

-0.02
vs -0.02

Q4.23

-2%

-0.02
vs -0.02

Q1.24

-3%

-0.03
vs -0.02

Q2.24

-5%

-0.05
vs -0.03

Institutionnal Ownership

QoQ

Q3.22

24

24
vs 22

9%

Q4.22

33

33
vs 24

38%

Q1.23

43

43
vs 33

30%

Q2.23

84

84
vs 43

95%

Q3.23

132

132
vs 84

57%

Q4.23

148

148
vs 132

12%

Q1.24

131

131
vs 148

-11%

Q2.24

118

118
vs 131

-10%

Earnings Growth

Latest News

MLTX

globenewswire.com

7 hours ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MLTX

businesswire.com

7 hours ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MLTX

globenewswire.com

8 hours ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MLTX

seekingalpha.com

8 hours ago

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

MLTX

globenewswire.com

8 hours ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MLTX

seekingalpha.com

14 hours ago

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

New Feature Coming Soon, Stay Tuned!

Shape

Shape